Amid rising drug costs and the growing influence of pharmacy benefit managers on patient care decisions, physicians are increasingly called upon to advocate for affordable, evidence-based treatments for their patients.

Amid rising drug costs and the growing influence of pharmacy benefit managers on patient care decisions, physicians are increasingly called upon to advocate for affordable, evidence-based treatments for their patients.
As the novel coronavirus that causes COVID-19 spreads across the globe, innovative thinking is needed more than ever to counter the devastating effects on the physical and socioeconomic health of individuals and communities. Innovations in healthcare delivery not yet fully realized prior to the pandemic, such as the adoption of telehealth, are moving to the…
Over the past 18 months, the ACR’s Quality of Care (QOC) Committee has helped produce an impressive number of resources that will help rheumatologists deliver the best possible care. Working through specific projects supervised under its Criteria, Guideline, Guidance, and Quality Measure subcommittees, the QOC Committee has developed new sets of disease criteria, clinical guidelines,…
In early June, the ACR released an updated guideline on the management of rheumatoid arthritis, which includes new recommendations for specific high-risk groups.1 The guideline includes 44 recommendations—seven of which are strong and 37 conditional. It underscores the role of methotrexate as a cornerstone therapy and emphasizes minimizing glucocorticoids, when possible. Guideline Development Process At…
When rheumatologists think about rheumatoid arthritis (RA), they are apt to picture the synovium, contemplate such antibodies as rheumatoid factor and those to citrullinated proteins, and consider how this interplay of factors manifests in disease. What is not as commonly discussed is the role the autonomic nervous system plays in the pathogenesis and symptomatology of…
David R. Karp, MD, PhD, & Christine Stamatos, DNP, ANP-C |
One thing that became clear very quickly this past year was that the COVID-19 pandemic would change the way we deliver care to patients. What has not changed amid an evolving healthcare landscape is our driving focus to ensure our patients’ access to rheumatology care and the availability of state-of-the-art treatments. We know you share…
On March 29, Brandon Elliot walked up to a 65-year-old Filipino American woman near Times Square and kicked her in the chest. Footage from the security camera of a nearby luxury apartment building recorded the attack: Elliot shoved her to the ground, and then repeatedly kicked and stomped on her, while shouting, “You don’t belong…
Frank A. Wollheim, MD, PhD, FRCP, MACR |
On Feb. 1, the Royal Swedish Academy of Sciences announced that Daniel L. Kastner, MD, PhD, scientific director of the Division of Intramural Research of the National Human Genome Research Institute, where he is a National Institutes of Health (NIH) Distinguished Investigator, was awarded the 2021 Crafoord Prize in Polyarthritis “for having established the concept…
In spring 2020, as it became obvious that COVID-19 wasn’t going anywhere anytime soon, the leaders of the Rheumatology Research Foundation implemented an expedited process to distribute research funding beyond its typical awards program. This resulted in the Foundation awarding $1.65 million to fund five research studies that will look at the relationships between rheumatic…
Marie Dardeno, DO, Joshua D. Sparling, MD, & William Monaco, MD |
Calciphylaxis, or calcific uremic arteriolopathy, is a rare disease characterized by calcification of the arterioles and capillaries in the dermis and subcutaneous tissue, resulting in thrombus formation and subsequent skin ischemia and necrosis.1 This serious condition most commonly occurs in patients with end-stage renal disease (ESRD) requiring dialysis or in kidney transplant recipients. In rare…